Cancer & Disease Research Sponsored by Beckman Coulter
Researchers discover important 2nd SARS-CoV-2 receptor
Researchers have identified a second receptor that might be important in SARS-CoV-2 infectivity, according to a new report published in Science on October 20. This cofactor helps facilitate virus-host cell interactions in cells with low levels of angiotensin-converting enzyme 2, the primary receptor on host cells, and might explain the increased pathogenicity of SARS-CoV-2.  Discuss
Passive vaccines with mAbs may be effective for COVID-19
Monoclonal antibodies (mAbs) isolated from the blood of recovered COVID-19 patients -- known colloquially as "convalescent plasma" -- could be potentially useful as therapeutic and prophylactic agents for passive vaccination, assuming their administration does not trigger unwanted side effects. The findings of the new study were published in Cell on September 26.  Discuss
Antibody fragments may be exceptionally effective against SARS-CoV-2
An engineered antibody fragment has been developed as a highly potent neutralizer of SARS-CoV-2. For the first time, one of these tiny molecules has been tested for efficacy in in vitro and in vivo infection models. The results of the collaborative study were published in Cell on September 14.  Discuss
Optofluidics technology accelerates discovery of COVID-19 treatments
Known for its transformative technology, Berkeley Lights is a pioneer in optofluidics, which has supported the biopharmaceutical industry for years with its deep cell characterization capabilities. These efforts are highlighted by the rapid impact that Berkeley Lights' Beacon systems had during the early days of the COVID-19 pandemic.  Discuss
New approach to cancer immunotherapies combines 2 mAb treatments
A new approach to increasing the effectiveness of current cancer immunotherapies combines existing therapies with new monoclonal antibodies (mAb) that block inhibitory cytokines in tumor microenvironments, allowing the body to effectively eliminate tumors. The results of the study were published in Nature Communications on September 11.  Discuss
Gum disease may affect COVID-19 severity
Patients with inflammation caused by periodontitis may experience more severe COVID-19 complications, according to an article published online July 30 in the Journal of the California Dental Association.  Discuss
New tools rapidly detect anti-SARS-CoV-2 antibodies
New tools using surrogate viruses may be useful for rapid testing to determine whether antibodies effectively neutralize SARS-CoV-2. The viral vector-based platform approach was published in the Journal of Experimental Medicine on July 21.  Discuss
NIH forms COVID-19 clinical trials network
The National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health (NIH), has established a new clinical trials network to conduct large-scale testing of COVID-19 vaccines and monoclonal antibodies.  Discuss
High-throughput analysis speeds downstream process development
Adding high-throughput analysis helped speed up downstream process development for drug candidates based on monoclonal antibodies, according to a case study presented June 17 during the BioProcess International Spring Digital Week 2020.  Discuss
Optofluidics aids cell line development for antibody-based therapies
Implementation of optofluidics in cell line development can help advance multiple lead candidate molecules with increased screening capacity. A researcher from GlaxoSmithKline discussed how her team uses an optofluidic system in a June 15 presentation at the BioProcess International Spring Digital Week's 2020 virtual meeting.  Discuss
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter